Navigation Links
Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
Date:3/3/2009

Infectious Diseases Company Featured on March 9th and 10th, 2009, at BioSquare Meeting in France, and March 17, 2009, at BioEurope in Italy

ROCKVILLE, Md., March 3 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products for infectious diseases of epidemic potential has announced that Alan Klein, Sequella Executive Vice President for Corporate Development, will participate in a Panel at the BioSquare 2009 Meeting at the Lyon Congress Center in Lyon, France. The Panel, entitled New Antibiotherapies for Tomorrow, will be held from 10:45 AM to 12:00 noon on March 9, 2009. The presentation will address antibiotic strategies of the 21st century and highlights both the most advanced and successful approaches and the characteristics of future opportunities.

Mr. Klein will also present at the same meeting on Tuesday, March 10, from 10:15 to 11:00 AM in Room St. Clair 2, 2nd floor, as part of the CNS & Infectious Diseases section of BioSquare 2009 at the Lyon Congress Center in Lyon, France.

Sequella will also present on March 17, 2009 at 5:00 PM in Room Yellow 3, Level 1, of the Infectious Diseases section at BioEurope Spring 2009 at the Milano Convention Centre in Milan, Italy.

"We look forward to participating in both of these European conferences and presenting new information regarding the progress of our product portfolio, while continuing partnership discussions that will appropriately monetize our assets," said Mr. Klein. To learn more about Sequella or their presentations at BioSquare or the BioEurope Spring conference, visit www.sequella.com.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
4. New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
5. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
6. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
7. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
8. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
9. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
10. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
11. Collaborative Software Initiative Addresses State Governments Requirements for Meeting Infectious Disease Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... annual report which summarizes and analyzes nearly 750 unique supply chain notifications ... and analysis service. , Supply chain risk management practitioners subscribe to the ...
(Date:2/3/2016)... Feb. 3, 2016  Today, Symphony Technology Group (STG) ... , a leading provider of primary research and analytics-based ... IMS Health , a global information and technology services ... and technologies will be integrated into IMS Health to ... market research capabilities. ...
Breaking Biology Technology:
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):